Hims Hers Health (HIMS)

Healthcare · Drug Manufacturers - Specialty & Generic
$29.47 -0.67% on the day Market cap $6.5B 52-week range $13.74 to $65.30 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Free cash flow growth the price needs
33% a year for 10 years

At a market value of $6.5B, Hims Hers Health's free cash flow of $41M (fiscal 2025) would need to grow about 33% a year for the stock to be worth today's price. That is faster than the company has grown its free cash flow over the last 2 years.

Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from Hims Hers Health's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.

Implied by the price32.9% a year
Free cash flow, last 2 years4.1% a year
Revenue, same period74.7% a year
Price to free cash flow159.3x

Fundamental grade

F

Five factors scored 1 to 9 from HIMS's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation2
Profitability2
Growth4
Financial health1
Cash efficiency4

Key numbers

P/E (trailing)69.8x
P/E (forward)71.8x
Price / free cash flow88.0x
EV / EBITDA152.1x
Price / sales2.53x
Price / book14.6x
Revenue growth+38.2%
Operating margin-6.0%
Net margin-5.5%
Return on equity-43.8%
Dividend yield—
Debt / equity10.2x

Results from SEC filings

Fiscal years, from Hims Hers Health's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20212022202320242025
Revenue$272M$527M$872M$1.5B$2.3B
Net income-$108M-$66M-$24M$126M$128M
Free cash flow-$39M-$38M$38M$187M$41M
EPS (diluted)-$0.58-$0.32-$0.11$0.53$0.51
Operating margin-42.3%-13.0%-3.4%4.2%4.5%

Where the revenue comes from

Revenue by regions, fiscal 2025.

United States Revenue$2.2B94%
Rest of the World Revenue$134M6%

Superinvestors who own HIMS

From each investor's latest 13F filing (what a 13F shows). 1 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Cliff Asness
AQR Capital Management
Added $7M0.00%Q2 2026

Insider buying

Open-market purchases by Hims Hers Health's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of HIMS in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when HIMS trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

What growth does Hims Hers Health's stock price imply?

At a market value of $6.5B, Hims Hers Health would need its free cash flow to grow about 33% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 2 years its free cash flow grew 4% a year.

Are Hims Hers Health insiders buying the stock?

No open-market insider purchases of HIMS in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own Hims Hers Health?

1 of the superinvestors Investingly tracks hold HIMS in their latest 13F, including Cliff Asness.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.